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Primary liver cancer has the second highest mortality rate 
with more than 700,000 deaths. Hepatocellular carcinoma 
(HCC), the most prevalent tumor type in the liver, arises 
predominantly from hepatocytes and is often related to 
known etiologies such as chronic hepatitis B or C virus, 
obesity, diabetes mellitus, metabolic liver diseases and 
life style factors (for example, alcohol). The injury to the 
liver parenchyma, these risk factors induce, causes an 
inflammatory milieu, which initiates a chain of accumulative 
events by producing reactive oxygen species (ROS), 
inflammatory cytokine and chemokine release as well as 
chromosomal instability. In this milieu, progressions of 
cellular death (necrosis) and regeneration result in liver 
fibrosis. In the background of the damaged liver, molecular 
alterations accrue contributing to the initiation of HCC. 
This multi-step progression and a detailed understanding 
of the genetic and epigenetic events that define HCC 
development remain challenging. The severity of this 
malignancy is further complicated since it commonly is 
associated with underlying cirrhosis, which clinically is 
problematic for the advancement of therapeutic options.
Recent studies have emphasized the molecular 
complexity in primary HCC, characterizing distinct 
interpatient tumor heterogeneity, including prevalent 
mutations in genes, such as TP53, CTNNB1, chromatin 
remodeling factors, and frequent early variants in the TERT 
promoter (1,2). Regardless of these targets, patients often 
response different to treatment or markedly show drug 
resistance. As such, essentially the last decade of clinical 
phase III trials has failed and the only approved therapy 
is the multi-tyrosine kinase inhibitors (sorafenib and 
regorafenib). This genomic tumor complexity is further 
underlined by a prominent intra-tumor heterogeneity 
(ITH) (3,4), which is defined as the morphologic diversity, 
differential phenotypic potential, and genome variance 
of distinct tumor cells comprising a single tumor mass. 
The model of “branched evolution” has emerged as a 
reflection of this tumor heterogeneity, including both the 
molecular and cellular convolution of the disease (tumor 
mass) that complicates accurate patient characterization 
and stratification as well as clinical management. HCC is 
typically innately resistant to treatment at diagnosis and 
from a therapeutic perspective, the heterogeneous branched 
evolution suggests only a partial sampling of a given tumor 
mass with apparent consequences to precision-based clinical 
decisions, and thus, limited or incomplete drug response. 
In  the  l i ve r,  th i s  s cenar io  i s  b roadened  by  a 
complexity in the putative “cell of origin” leading to 
malignant transformation, including evidence of cellular 
dedifferentiation resulting in the hepatocytic lineage 
to give rise to tumor formation in the intrahepatic bile 
ducts (5,6), suggesting a marked continuum both genotypic 
and phenotypic of the malignant cells in the liver (7). 
This quandary is further complicated by an anticipated 
outgrowth of dormant cancer cells that present a distinctly 
different drug response or adaptation to therapy.
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Recent integromics studies, including The Cancer 
Genome Atlas (TCGA) (8) and Thailand Initiative in 
Genomics and Expression Research for Liver Cancers 
(TIGER-LC) (9) have both characterized new patient 
subclasses and drug targets. Moreover, these consortia-
led approaches have additionally stressed the potential for 
introducing immunotherapy into liver cancer management. 
As such, 22% (43/196) of the HCC cases presented by 
histopathological evaluation (TCGA core patient set) show 
high to moderate levels of tumor infiltrating lymphocytes 
(TIL). Hierarchical clustering of patient-based gene 
expression of immune surface markers outlined two groups 
with elevated expression of key immune checkpoint genes 
CTLA-4, PDCD1 and CD274/PD-L1. Irrespective of viral 
disease status (hepatitis B or C viral infection), a significant 
difference in the immune cell composition was determined 
between tumor and the adjacent surrounding liver, with the 
tumor microenvironment (TME) demonstrating a change 
in the immune cell composition from activating effector 
cells to resting suppressive immune cells. This includes 
depletion of naïve B cells, neutrophils, monocytes and 
gamma/delta T cells as well as enrichment of memory B 
cells, regulatory T cells (Tregs), resting dendritic cells (DCs) 
and undifferentiated (M0) macrophages. 
Given the importance of TME for the main clinical 
hurdles (immunosuppression, chemoresistance and 
metastasis) in both localized and non-localized disease, 
targeting the immune compartment of the tumor mass has 
noticeably altered clinical oncology. Predictive factors of 
response to immunotherapy include mutational burden, 
TIL levels, and expression of the markers CTLA-4, PDCD1 
and PD-L1. Information about the tumor-residing T 
cells is dependent on and, as such, vital for understanding 
the efficacy of immunotherapy. The premise of immune 
treatment is in the TME to release a cytotoxic response, 
which is elicited by CD8+ T cells, an activity that often is 
abrogated either through suppression of Tregs or T cell 
exhaustion (abrogated T cell effector function). In this view, 
though HCC often has high levels of TILs, this tumor 
type remains immunologically challenging since the TIL 
function/effect is deregulated.
In work recently presented in Cell (10), Zheng and 
colleagues provided a comprehensive transcriptomic and T 
cell receptor (TCR) map of more than 5,000 single tumor-
infiltrating T cells isolated by FACS from blood, adjacent 
normal and tumor tissues obtained from six individual HCC 
patients. Remarkably, a total of 11 unique T cell subsets 
were elucidated by transcriptomics, defining 5 CD8+ 
(cluster C1–C5) and 6 CD4+ (cluster C6–C11) sub-clusters 
represented by distinct gene signatures. Importantly, each 
of these T cell subsets revealed a tissue-specific distribution 
with additional evidence of developmental gene expression 
connectivity. Notably, utilizing SC3 clustering each of 
the major clusters were dominated by a unique T cell 
representation. The functional presentation emphasized 
characteristics of each cluster with C1 expressing naïve 
marker genes (for example, LEF1) associated with peripheral 
blood, C2 distinguished by T cell effector function, 
C3 comprising genes (SLC4A10) related to mucosal-
associated invariant T (MAIT) cells prevalent in the 
adjacent normal liver tissue whereas C4–C5 predominantly 
are composed of tumor-associated CD8+ exhausted T cells 
represented by markers CTLA4, PDCD1 and differential 
regulation of the GZMK expression signature. The residual 
six clusters (C6–C11) were dominated by CD4+ T cells with 
C6 primarily originating from peripheral blood, C7–C8 
both represented FOXP3+ Tregs (CD4+/CD25high) with 
either of the sub-clusters main expression pattern involved 
in blood or tumor tissue, respectively. CD4+ Tregs are 
further defined by key expression of genes such as FOXP3, 
TNFRSF9, TIGIT and CTLA4. The last three clusters 
(C9–C11) are predominantly associated with T helper 
cell gene expression characteristics with C10 associated to 
exhausted CD4+ cells (CXCL13, PDCD1, CTLA4, TIGIT) 
and elevated cytotoxic marker-gene expression (NKG7, 
GNLY, GZMB) in cluster C11. This study presents for the 
first time a comprehensive evidence for a differential T cell 
distribution in the TME of HCC, revealing both known 
and novel marker genes associated with TILs specifically 
underlining the presence of exhausted CD8+ T cells and 
Tregs by for example marker genes CCR8 and LAYN. 
Interestingly, the gene LAYN is associated with exhausted 
CD8+ TILs and poor prognosis. Upon T cell (CD8+ 
and Treg) activation LAYN is elevated, whereas LAYN 
expression attenuates the expression of interferon gamma 
by CD8+ T cells, which is required for active tumor cell 
killing (Figure 1). 
In HCC, the TME presents an augmented existence 
of exhausted CD8+ T cells and Tregs. Importantly, clonal 
TCR findings suggest that tumor-associated Tregs are 
recruited since 82% of Tregs in the tumor are unique, and 
thus, do not show evidence of evolution directly from the 
tumor-residing CD4+ T cells or expansion of Treg derived 
from the tumor-adjacent normal tissue. Contrary, exhausted 
CD8+ T cell clones demonstrated similarity with 37% 
shared between CD8+ clusters (C1–C5), which suggests a 
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transformation of T cells within the tumor into exhausted 
CD8+ T cells. As such, C5 (tumor-associated exhausted 
CD8+ T cell expression) was proposed to present a possible 
cluster/profile harboring T cell expression signaling that 
may be suggestive of a transition from effector to exhausted 
T cells within the tumor. These cells may be candidates 
for therapeutic targeting, stimulating their effector T cell-
like phenotype to revive their T cell function and avoid 
regulatory exhaustion. Additional, C9 was highlighted as 
a putative route for immunotherapy to promote cytolytic 
CD4+ T cell function. Current clinical trials, which utilize 
immunotherapy in HCC, include Keynote-224 (phase II 
to estimate activity and toxicity of pembrolizumab, n=100), 
another phase II trial will investigate pembrolizumab 
in advanced unresectable HCC cases, CheckMate-040 
(phase I–II to determine the safety of nivolumab) and 
CheckMate-459 (phase III trial that will investigate 
nivolumab vs. sorafenib with primary endpoints overall 
survival and time to progression, n=726) (11). 
In conclusion, the purpose of immunotherapies is 
essentially to modify the TME both within the primary 
tumor site and metastatic niche(s) in order to increase the 
level of active tumor-specific CD8+ effector cells relative to 
suppressive T cells, inflammatory cells and their mediators. 
Additional, the goal is to induce a systemic memory eliciting 
an anti-tumor immune-response and thus, to control 
residual tumor cells. In the current study, the authors 
have defined a comprehensive map of the circulating and 
tumor-residing T cells, underscoring their unique genomic 
characteristics and emphasizing a path for immunotherapy 
in HCC.
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Figure 1 Patient with liver cancer. The population of tumor infiltrating lymphocytes (TILs) CD4 and CD8 T cells hepatocellular carcinoma 
(HCC) is represented by a specific enrichment of exhausted CD8 and regulatory T cells. A signature key gene layilin (LAYN) is increased in 
activated CD8 and regulatory CD4 T cells and causes the repression of interferon gamma expression, which is required for active tumor cell 
killing. This results in the suppression of regulatory CD4 and exhaustion of CD8 T cells. 
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